Stay updated with breaking news from Michael Strapazon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The study met its primary objective of demonstrating statistically greater improvement from baseline in Eczema Area and Severity Index score at 16 weeks versus placeboPatients receiving KHK4083/AMG 451 showed statistically greater improvements in additional secondary efficacy endpoints versus placeboKHK4083/AMG 451...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized...
Amgen today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRAS TM in previously treated patients with non-small cell lung cancer during the 2021 American Society of Clinical Oncology Annual Meeting. These data were also simultaneously published in the New England Journal of Medicine . The publication includes mature overall ...
THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ -- Amgen will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese,... | June 4, 2021
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical...